Clobetasone butyrate and hydrocortisone butyrate in the treatment of eczema: a double-blind comparison.

Abstract

Forty patients with symmetrical eczematous lesions on their extremities were treated in a double-blind fashion with 0.05% clobetasone butyrate and 0.1% hydrocortisone butyrate in cream bases. After 2 weeks of treatment, a preference for clobetasone butyrate was observed in 7 cases, for hydrocortisone butyrate in 9 cases and in 24 cases both sides responded equally. The lesions on both sides improved steadily throughout the study in all cases. When completing the trial after 2-weeks' treatment, the clobetasone butyrate-treated lesions had healed in 8 cases and the hydrocortisone butyrate-treated lesions in 10 cases. No local side-effects were observed.

• Authors: A Lassus
• Journal: Current medical research and opinion (Curr Med Res Opin) Vol. 6 Issue 3 Pg. 165-7 ( 1979) ISSN: 0300-7995 [Print] England
• PMID: 391489 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Anti-Inflammatory Agents
• clobetasone butyrate
• Betamethasone
• Clobetasol
• Hydrocortisone

Topics

• Administration, Topical
• Adolescent
• Adult
• Aged
• Anti-Inflammatory Agents (adverse effects, therapeutic use)
• Betamethasone (analogs & derivatives, therapeutic use)
• Clinical Trials as Topic
• Clobetasol (adverse effects)
• Double-Blind Method
• Eczema (drug therapy)
• Female
• Humans
• Hydrocortisone
• Male
• Middle Aged
• Time Factors